The short version of GHS-R1a fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Journal of Molecular Biology. 206 (4): 759–777. doi:10.1016/0022-2836(89)90583-4. PMID 2500530. Milner-White, E (1990). "Situations of gamma-turns in proteinsTheir relation to alpha-helices, beta-sheets and ligand binding sites". J. Mol. Biol. 216 (2): 385–397. doi:10.1016/S0022-2836(05)80329-8. PMID 2254936. Hutchinson, E.G.; Thornton, J.M. (1994). "A revised set of potentials for β-turn formation in proteins". Protein Science. 3 (12): 2207–2216. doi:10.1002/pro.5560031206. PMC 2142776. PMID 7756980. Pavone V, Gaeta G, Lombardi A, Nastri F, Maglio O, Isernia C, Saviano M (1996). "Discovering protein secondary structures: classification and description of isolated alpha-turns". Biopolymers. 38 (6): 705–21. doi:10.1002/(SICI)1097-0282(199606)38:6<705::AID-BIP3>3.0.CO;2-V. PMID 8652792. Rajashankar KR, Ramakumar S (1996). "Pi-turns in proteins and peptides: Classification, conformation, occurrence, hydration and sequence". Protein Sci. 5 (5): 932–46. doi:10.1002/pro.5560050515. PMC 2143406. PMID 8732765.{{cite journal}}: CS1 maint: deprecated archival service (link) Shapovalov, M; Vucetic, S; Dunbrack RL, Jr (March 2019). "A new clustering and nomenclature for beta turns derived from high-resolution protein structures". PLOS Computational Biology. 15 (3) e1006844. Bibcode:2019PLSCB..15E6844S. doi:10.1371/journal.pcbi.1006844. PMC 6424458. PMID 30845191.
== Stages of the CKM syndrome == The CKM syndrome is defined as having the stages listed in the following table. The table also gives the relative mortality rates of Stages 1 to 4 compared to stage 0 based on the study of 97,777 Chinese patients over a medium follow-up time of 15 years. The study found that there was a highly significant (p<0.001) increased mortality (causes not specified) with increasing stages of disease.
Proteins, unlike nucleic acids, can have varying charges and complex shapes, therefore they may not migrate into the polyacrylamide gel at similar rates, or all when placing a negative to positive EMF on the sample. Proteins, therefore, are usually denatured in the presence of a detergent such as sodium dodecyl sulfate (SDS) that coats the proteins with a negative charge. Generally, the amount of SDS bound is relative to the size of the protein (usually 1.4g SDS per gram of protein), so that the resulting denatured proteins have an overall negative charge, and all the proteins have a similar charge-to-mass ratio. Since denatured proteins act like long rods instead of having a complex tertiary shape, the rate at which the resulting SDS coated proteins migrate in the gel is relative only to their size and not their charge or shape. Proteins are usually analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), by blue native or clear native PAGE, by preparative native PAGE, or by 2-D electrophoresis. Characterization through ligand interaction may be performed by electroblotting or by affinity electrophoresis in agarose or by capillary electrophoresis as for estimation of binding constants and determination of structural features like glycan content through lectin binding.
Sources: en.wikipedia.org
== Impact of the altered protein binding == Only the unbound fraction of the drug undergoes metabolism in the liver and other tissues. As the drug dissociates from the protein, more and more drug undergoes metabolism. Changes in the levels of free drug change the volume of distribution because free drug may distribute into the tissues leading to a decrease in plasma concentration profile. For the drugs which rapidly undergo metabolism, clearance is dependent on the hepatic blood flow. For drugs which slowly undergo metabolism, changes in the unbound fraction of the drug directly change the clearance of the drug. The most commonly used methods for measuring drug concentration levels in the plasma measure bound as well as unbound fractions of the drug. The fraction unbound can be altered by a number of variables, such as the concentration of drug in the body, the amount and quality of plasma protein, and other drugs that bind to plasma proteins. Higher drug concentrations would lead to a higher fraction unbound, because the plasma protein would be saturated with drug and any excess drug would be unbound. If the amount of plasma protein is decreased (such as in catabolism, malnutrition, liver disease, renal disease), there would also be a higher fraction unbound. Additionally, the quality of the plasma protein may affect how many drug-binding sites there are on the protein.
=== Cell-free systems === E. coli cell lysate containing the cellular components required for transcription and translation are used in this in vitro method of protein production. The advantage of such system is that protein may be produced much faster than those produced in vivo since it does not require time to culture the cells, but it is also more expensive. Vectors used for E. coli expression can be used in this system although specifically designed vectors for this system are also available. Eukaryotic cell extracts may also be used in other cell-free systems, for example, the wheat germ cell-free expression systems. Mammalian cell-free systems have also been produced.
According to historian Michael Worboys, malnutrition was essentially discovered, and the science of nutrition established, between World War I and World War II. Advances built on prior works like Casimir Funk's 1912 formulisation of the concept of vitamins. Scientific study of malnutrition increased in the 1920s and 1930s, and grew even more common after World War II. Non-governmental organizations and United Nations agencies began to devote considerable energy to alleviating malnutrition around the world. The exact methods and priorities for doing this tended to fluctuate over the years, with varying levels of focus on different types of malnutrition like Kwashiorkor or Marasmus; varying levels of concern on protein deficiency compared to vitamins, minerals and lack of raw calories; and varying priorities given to the problem of malnutrition in general compared to other health and development concerns. The green Revolution of the 1950s and 1960s saw considerable improvement in capability to prevent malnutrition. One of the first official global documents addressing Food security and global malnutrition was the 1948 Universal Declaration of Human Rights(UDHR). Within this document it stated that access to food was part of an adequate right to a standard of living. The Right to food was asserted in the International Covenant on Economic, Social and Cultural Rights, a treaty adopted by the United Nations General Assembly on December 16, 1966. The Right to food is a human right for people to feed themselves in dignity, be free from hunger, food insecurity, and malnutrition.
The two substrates of this enzyme are D-xylose and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are D-xylono-1,5-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-xylose:NADP+ 1-oxidoreductase. Other names in common use include D-xylose (nicotinamide adenine dinucleotide phosphate), dehydrogenase, D-xylose-NADP+ dehydrogenase, D-xylose:NADP+ oxidoreductase, and D-xylose 1-dehydrogenase (NADP+).
Sources: en.wikipedia.org
Macro-creatine kinase (macro-CK) is a macroenzyme, an enzyme of high molecular weight and prolonged half-life found in human serum. It is one of the most common macroenzymes. Macro-CK type 1 is a complex formed by one of the creatine kinase isoenzyme types, typically CK-BB, and antibodies; typically IgG, sometimes IgA, rarely IgM. Macro-CK type 2 is formed from mitochondrial CK polymer. Macro-CK type 1 has been associated with autoimmune and other chronic conditions. Macro-CK type 2 has been associated with malignancy. Macro-CK has been implicated as a source of interference in interpretation of medical labs.
Winning percentage: 70.5% at International circuit & 78.9% at National circuit Podium percentage: 86.9% at International circuit & 94.7% at National circuit Top 5 percentage: 95.1% at International circuit & 100.0% at National circuit
It tends not to share the common blue tint with a vein however. It can be felt as a hardened lump or "vein" even when the penis is flaccid, and is even more prominent during an erection. It is considered a benign physical condition. It is fairly common and can follow a particularly vigorous sexual activity for men, and tends to go away if given rest and more gentle care, for example by use of lubricants. Carcinoma of the penis is rare with a reported rate of 1 person in 100,000 in developed countries. Some sources state that circumcision can protect against this disease, but this notion remains controversial among medical circles. Hard flaccid syndrome is a rare, chronic condition characterized by a flaccid penis that remains in a firm, semi-rigid state in the absence of sexual arousal. Cold glans syndrome is a condition marked by the persistent inability of the glans penis to maintain an erect state during sexual arousal, potentially leading to reduced sensitivity and erection difficulties.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.